Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners, and colleagues to discover, develop and deliver therapies for genetically defined diseases. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust pipeline of investigational medicines, including a first-in-class pyruvate kinase R (PKR) activator that is being evaluated for the treatment of three distinct hemolytic anemias – pyruvate kinase (PK) deficiency, alpha- and beta-thalassemia and sickle cell disease. In addition to its active late-stage clinical pipeline, Agios has multiple novel investigational therapies in clinical and preclinical development